IR@PKUHSC  > 北京大学临床肿瘤学院
学科主题临床医学
Prevalence of A2143G mutation of H-pylori-23S rRNA in Chinese subjects with and without clarithromycin use history
Liu, Zhuoqi1,2,3,4; Shen, Jing1,2,3; Zhang, Lian1,2,3; Shen, Lin1,2,3; Li, Qiang1,2,3; Zhang, Baozhen1,2,3; Zhou, Jing1,2,3; Gu, Liankun1,2,3; Feng, Guoshuang1,2,3; Ma, Junling1,2,3; You, Wei-Cheng1,2,3; Deng, Dajun1,2,3
刊名BMC MICROBIOLOGY
2008-05-28
DOI10.1186/1471-2180-8-81
8
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Microbiology
研究领域[WOS]Microbiology
关键词[WOS]23S RIBOSOMAL-RNA ; RESISTANT HELICOBACTER-PYLORI ; THERAPY ; PCR ; ERADICATION ; INFECTION ; POPULATION ; DIVERSITY ; SEQUENCE ; LESIONS
英文摘要

Background: A2143G mutation of 23S rRNA gene of H. pylori results in clarithromycin (CLR) resistance. To investigate the prevalence of the CLR resistance-related A2143G mutation of the H. pylori-specific 23S rRNA gene in Chinese subjects with and without CLR use history, 307 subjects received the treatment with amoxicillin and omeprazole (OA) and 310 subjects received a placebo in 1995, and 153 subjects received a triple therapy with OA and CLR (OAC) in 2000. DNA was extracted from fasting gastric juice at the end of the intervention trial in 2003. H. pylori infection was determined by H. pylori-specific 23S rRNA PCR, ELISA, and (13)C-urea breath test assays. Mutations of the 23S rRNA gene were detected by RFLP assays.

Results: The presence of 23S rRNA due to H. pylori infection in the OA group remained lower than that in the placebo group 7.3 yrs after OA-therapy [51.1% (157/307) vs. 83.9% (260/310), p = 0.0000]. In the OAC group, the 23S rRNA detection rate was 26.8% (41/153) three yrs after OAC-treatment. The A2143G mutation rate among the 23S rRNA-positive subjects in the OAC group [31.7% (13/41)] was significantly higher than that in the OA group [10.2% (16/157)] and the placebo group [13.8% (36/260)]. The frequency of the AAGGG -> CTTCA (2222-2226) and AACC. GAAG (2081-2084) sequence alterations in the OAC group was also significantly higher than those in the OA group and the placebo group.

Conclusion: Primary prevalence of the A2143G mutation was 10 similar to 14% among Chinese population without history of CLR therapy. Administration of CLR to eliminate H. pylori infection increased the prevalence of the A2143G mutation in Chinese subjects (32%) significantly.

语种英语
WOS记录号WOS:000257076200001
Citation statistics
Cited Times:11[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/65129
Collection北京大学临床肿瘤学院
北京大学第一临床医学院_整形烧伤外科
北京大学临床肿瘤学院_消化肿瘤内科
北京大学临床肿瘤学院_病因学研究室
北京大学临床肿瘤学院_流行病学研究室
北京大学临床肿瘤学院_中心实验室
北京大学临床肿瘤学院_党院办公室
作者单位1.Peking Univ, Sch Oncol, Beijing 100036, Peoples R China
2.Beijing Inst Canc Res, Beijing 100036, Peoples R China
3.Beijing Canc Hosp, Beijing 100036, Peoples R China
4.Nanchang Univ Med Coll, Nanchang 330006, Peoples R China
Recommended Citation
GB/T 7714
Liu, Zhuoqi,Shen, Jing,Zhang, Lian,et al. Prevalence of A2143G mutation of H-pylori-23S rRNA in Chinese subjects with and without clarithromycin use history[J]. BMC MICROBIOLOGY,2008,8.
APA Liu, Zhuoqi.,Shen, Jing.,Zhang, Lian.,Shen, Lin.,Li, Qiang.,...&Deng, Dajun.(2008).Prevalence of A2143G mutation of H-pylori-23S rRNA in Chinese subjects with and without clarithromycin use history.BMC MICROBIOLOGY,8.
MLA Liu, Zhuoqi,et al."Prevalence of A2143G mutation of H-pylori-23S rRNA in Chinese subjects with and without clarithromycin use history".BMC MICROBIOLOGY 8(2008).
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Liu, Zhuoqi]'s Articles
[Shen, Jing]'s Articles
[Zhang, Lian]'s Articles
百度学术
百度学术Similar articles in
[Liu, Zhuoqi]'s Articles
[Shen, Jing]'s Articles
[Zhang, Lian]'s Articles
必应学术
必应学术Similar articles in
[Liu, Zhuoqi]'s Articles
[Shen, Jing]'s Articles
[Zhang, Lian]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.